两家公司管理团队均来自辉瑞收购的Array
As $OnKure(OKUR)$ awaits a key catalyst in release of the first substantial human data for its lead project, OKI-219, it might take heart that this is no longer the industry’s only clinical-stage PI3Kα inhibitor specific for the H1047R mutation. That was the case until this month, when $Cogent Biosciences(COGT)$ started a phase 1 study with its contender, CGT6297, a new listing on clinicaltrials.gov reveals.